The medication was approved for chronic weight management with patients who have obesity or who are overweight with at least one weight-related condition
It may not be suitable for those who are pregnant, breastfeeding, or have certain autoimmune conditions
McDaid, A novel indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
Exposure to light and heat can cause chemical changes in the medication, which might make it less effective
Monitoring for side effects: Patients starting semaglutide should be closely monitored for serious side effects, like: Pain in the upper part or middle of the stomach that spreads to the back Allergic reaction Decreased urination and swelling of the feet, legs, or ankles Changes in vision Fainting or dizziness Yellow eyes (jaundice), dark urine, or clay-colored stools Rapid heartbeat Sweating, confusion, drowsiness, headache, or blurred vision Customizing a treatment plan: Semaglutide should be tailored to each patients unique health profile, including their cardiovascular risk and comorbidities
.jpg)